



(11) **EP 3 607 940 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 72

(51) Int Cl.:
A61K 9/50 ^(2006.01) **A61K 31/496** ^(2006.01)
A61K 47/34 ^(2017.01) **A61K 9/10** ^(2006.01)
A61P 25/18 ^(2006.01)

(48) Corrigendum issued on:
01.04.2020 Bulletin 2020/14

(86) International application number:
PCT/CN2018/090345

(43) Date of publication:
12.02.2020 Bulletin 2020/07

(87) International publication number:
WO 2019/218409 (21.11.2019 Gazette 2019/47)

(21) Application number: **18917042.6**

(22) Date of filing: **08.06.2018**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

- **XU, Peng**
Zhuhai City
Guangdong 519090 (CN)
- **WANG, Yanqing**
Zhuhai City
Guangdong 519090 (CN)
- **REN, Bing**
Zhuhai City
Guangdong 519090 (CN)
- **CHEN, Miaoli**
Zhuhai City
Guangdong 519090 (CN)
- **CHEN, Yanhua**
Zhuhai City
Guangdong 519090 (CN)
- **JIANG, Xiaoman**
Zhuhai City
Guangdong 519090 (CN)

(30) Priority: **16.05.2018 CN 201810468934**

(71) Applicant: **Livzon Pharmaceutical Group Inc.**
Zhuhai, Guangdong 519020 (CN)

- (72) Inventors:
- **LU, Wenqi**
Zhuhai City
Guangdong 519090 (CN)
 - **CHEN, Bin**
Zhuhai City
Guangdong 519090 (CN)
 - **KONG, Xiangsheng**
Zhuhai City
Guangdong 519090 (CN)

(74) Representative: **Uexküll & Stolberg**
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg (DE)

(54) **ARIPIRAZOLE SUSTAINED-RELEASE MICROSPHERE AND PREPARATION METHOD THEREFOR**

(57) The present invention provides an aripiprazole sustained release microsphere and a preparation method thereof, and the microsphere comprises aripiprazole and poly(lactide-co-glycolide), wherein the microsphere shows a spherical network framework structure with reticular pores being distributed over the spherical surface, and aripiprazole is filled in the pores. The microsphere has an average particle size of less than 20 μm , and the content of aripiprazole is 65%-80% of the total weight of

the microsphere. Since the aripiprazole sustained release microsphere of the present invention has an average particle size of less than 20 μm , it is applicable to a 5-gauge needle, thereby reducing pain in patients. In addition, the microsphere of the present invention can quickly reach an effective drug concentration in the early stage of administration without the need for oral administration to achieve the therapeutic effect, and does not generate a burst release effect.




Figure 1